McKesson Bets on Oncology, Biopharma as It Streamlines Portfolio [Yahoo! Finance]
McKesson Corporation (MCK)
Last mckesson corporation earnings: 2/4 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
investor.mckesson.com
Company Research
Source: Yahoo! Finance
Long known as one of the largest pharmaceutical distributors in North America, the company is now focusing on expanding its higher-margin services in oncology, multispecialty care and biopharma solutions. McKesson is positioning itself for sustainable long-term growth through technology, automation and specialized care, while preparing to separate its Medical-Surgical business to sharpen focus. Short-Term Growth Drivers McKesson is benefiting from strong momentum in pharmaceutical distribution and specialty therapy demand. The U.S. pharmaceutical market is expected to grow at a 7% CAGR between 2019 and 2029, with specialty drugs accounting for an increasing share. Oncology spending alone is projected to expand 60% from 2025 to 2029, directly supporting McKesson's oncology-focused platforms. Management has guided for fiscal 2026 adjusted operating profit of $6.2-$6.4 billion, adjusted EPS of $38.05-$38.55 and a free cash flow of $4.4-$4.8 billion. These targets reflect robust o
Show less
Read more
Impact Snapshot
Event Time:
MCK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCK alerts
High impacting McKesson Corporation news events
Weekly update
A roundup of the hottest topics
MCK
News
- McKesson (NYSE:MCK) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- McKesson (NYSE:MCK) had its "buy (a-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints [Yahoo! Finance]Yahoo! Finance
- McKesson Corporation (MCK) Strong Quarter Spurs Analyst Confidence [Yahoo! Finance]Yahoo! Finance
- McKesson (NYSE:MCK) had its "buy (b+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
MCK
Earnings
- 11/5/25 - Beat
MCK
Sec Filings
- 11/17/25 - Form 25-NSE
- 11/10/25 - Form 4
- 11/6/25 - Form 10-Q
- MCK's page on the SEC website